Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK/Medicago COVID-19 Vaccine Looks Like Also-Ran But Antibody Shows Value Against Omicron

Sotrovimab’s Sustained Efficacy Confirmed

Executive Summary

GSK looks unlikely to be a major player in COVID-19 vaccines, even in boosters, but its partnership with Vir could pay off handsomely.

You may also be interested in...



GSK Poaches New Vaccines R&D Chief From Pfizer

Phil Dormitzer has been headhunted to help GSK get up to speed in RNA and other vaccine platforms.

Harvest Time? Medicago And GSK Expect Summer Readout For Plant-Based COVID Vaccine

Medicago’s vaccine has generated a strong immune responses in a Phase II trial, which could see it finally reap the benefits of its plant-based technology.

Bavarian Nordic Rises As It Meets Demand For Monkeypox Vaccine

The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145541

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel